Preventing blood loss in Septoplasty and FESS using Dexmedetomidine or Clonidine premedicatio
Phase 3
Completed
- Conditions
- Health Condition 1: J329- Chronic sinusitis, unspecified
- Registration Number
- CTRI/2018/05/013896
- Lead Sponsor
- SDM college of medical science and hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 98
Inclusion Criteria
1. ASA PS 1 or ASA PS 2, undergoing Septoplasty and FESS
2. Willing to participate
Exclusion Criteria
1. ASA PS >3
2. Basal heart rate < 60 bpm
3. Pregnant women
4. Lactating mother
5. Hepatic, Renal or Cardiac abnormalities
6. Known case of coagulopathy
7. Allergic to Dexmedetomidine or Clonidine
8. Psychiatric disorder or Cognitive delay
9. Active LRTI or cases of Brochial asthma
10. Refusal to participate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess change in haematocrit during the intraoperative periodTimepoint: To assess change in haematocrit during the intraoperative period by calculating pre-op, post-op and suction jar Hb/PCV
- Secondary Outcome Measures
Name Time Method Amount of Fentanyl used peri-operativelyTimepoint: Total usage, calculated at the end of the surgery;Heart rate variabilityTimepoint: Baseline, before & after premedication, prior induction, after intubation, 5,10,15,30,45,60,75,90,105,120,135,150,165,180 minutes after incision;Surgeon satisfaction scoreTimepoint: End of surgery;Surgical field assessmentTimepoint: End of surgery